IRDOpus Genetics, Inc.
What is the market doing?
In an uptrend. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In an uptrend, above its rising 50- and 200-day averages. Oversold (RSI 30). Price is +10% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How IRD is trading
Opus Genetics, Inc. is +119% over the past year while the S&P 500 is +18%: 101 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +10%
vs 200-day average · a clear uptrend
- RSI (14)
- 30
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 27%
Below its 52-week high
Details›
- Last close2026-10-08
- $4.45
- 1 monthS&P 500 +1.6%
- −22%
- 1 yearS&P 500 +18%
- +119%
- 5 yearsS&P 500 +86%
- −14%
- vs 50-day average$4.43
- +0.51%
- 52-week high
- $6.09
- 52-week low
- $1.74
- Annualised volatility
- 79%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$7.6M
| Year | Return |
|---|---|
| 2026 (year to date) | +121% |
| 2025 | +69% |
| 2024 | −60% |
| 2023 | −15% |
| 2022 | −5.4% |
| 2021 | −43% |
| 2020 | −15% |
| 2019 | −83% |
| 2018 | −54% |
| 2017 | +44% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +5.9% |
| Feb | 10 | 4 of 10 | +8.7% |
| Mar | 10 | 3 of 10 | +1.6% |
| Apr | 10 | 4 of 10 | −1.3% |
| May | 10 | 4 of 10 | −1.8% |
| Jun | 10 | 4 of 10 | −4.4% |
| Jul | 11 | 4 of 11 | −0.62% |
| Aug | 11 | 5 of 11 | −5.3% |
| Sep | 11 | 6 of 11 | +3.2% |
| Oct | 11 | 3 of 11 | −8.6% |
| Nov | 10 | 4 of 10 | +1.3% |
| Dec | 10 | 4 of 10 | −1.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.